HLS-Rugged point-of-care device for global hemostasis testing of whole blood

描述(申请人提供)：德国莱茵集团正在开发一种使用全血的全球止血测试。它将使与创伤相关的凝固性疾病的诊断和目标定向治疗变得更快。它将降低与血液产品治疗相关的发病率、死亡率和成本。我们的设备测量凝血时间、动力学、硬度和裂解。与现有的不同 我们的仪器将使用廉价的一次性微流控试纸和坚固耐用的分析仪。我们的目标是改善对许多患者的护理--仅在美国就有多达620万人--他们出现凝血功能障碍，死亡几率增加了两倍。与此同时，我们可以为每个患者节省数百美元，为医院系统节省数十万美元。

DESCRIPTION (provided by applicant): Rheomics is developing a global hemostasis test that uses whole blood. It will enable faster diagnosis and goal-directed therapy of coagulopathies associated with trauma. It will reduce morbidity, mortality, and costs associated with blood product therapy. Our device measures clotting time, kinetics, stiffness, and lysis. Unlike existing devices, ours will use an inexpensive, disposable microfluidic test strip and a robust, easy-to-use analyzer. Our goal is to improve care for the many patients-as many as 6.2 million, just in the US-who develop a coagulation dysfunction that triples their chance of dying. At the same time, we can save hundreds of dollars per patient and hundreds of thousands of dollars for hospital systems.